Antitrust Antitrust

Leadiant to appeal Italian antitrust sanction that 'undermines' EU policy on orphan drugs

By Nicholas Hirst
  • 02 Jun 2022 17:25
  • 02 Jun 2022 17:25
Leadiant has said it will appeal a 3.5 million-euro Italian antitrust fine ($3.8 million) for raising the price of a life-saving drug to "unjustifiably high" levels.

In a statement, the company said the Tuesday decision risked discouraging companies from bringing drugs to market for rare diseases.

The fine was

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News